• 1
    Povoa P. C-reactive protein: a valuable marker of sepsis. Intensive Care Med 2002; 28: 235243.
  • 2
    Povoa P, Coelho L, Almeida E et al. Pilot study evaluating C-reactive protein levels in the assessment of response to treatment of severe bloodstream infection. Clin Infect Dis 2005; 40: 18551857.
  • 3
    Povoa P, Coelho L, Almeida E et al. C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. Eur Respir J 2005; 25: 804812.
  • 4
    Presterl E, Staudinger T, Pettermann M et al. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am J Respir Crit Care Med 1997; 156: 825832.
  • 5
    Coelho L, Povoa P, Almeida E et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007; 11: R92.
  • 6
    Seppa Y, Bloigu A, Honkanen PO, Miettinen L, Syrjala H. Severity assessment of lower respiratory tract infection in elderly patients in primary care. Arch Intern Med 2001; 161: 27092713.
  • 7
    Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121: 219225.
  • 8
    Gradel KO, Søgaard M, Dethlefsen C, Nielsen H, Schønheyder HC. Magnitude of bacteraemia is a predictor of mortality during 1 year of follow-up. Epidemiol Infect 2008; 137: 94101.
  • 9
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373383.
  • 10
    Hosmer DW Jr, Lemeshow S. Model development. In: HosmerDWJr, LemeshowS, eds. Applied survival analysis, 1st edn. New York: Wiley, 1999; 158195.
  • 11
    Harrell FE, ed. Regression modeling strategies with applications to linear models, logistic regression and survival analysis, 1st edn. New York: Springer-Verlag, 2001.
  • 12
    Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28: 964974.
  • 13
    Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000; 28: 6873.
  • 14
    Örtqvist A, Hedlund J, Wretlind B, Carlström A, Kalin M. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 1995; 27: 457462.
  • 15
    Menendez R, Martinez R, Reyes S et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64: 587591.
  • 16
    Söderquist B, Sundqvist KG, Jones I, Holmberg H, Vikerfors T. Interleukin-6, C-reactive protein, lactoferrin and white blood cell count in patients with S. aureus septicemia. Scand J Infect Dis 1995; 27: 375380.
  • 17
    Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25: 127141.
  • 18
    Leibovici L, Samra Z, Konigsberger H, Drucker M, Ashkenazi S, Pitlik SD. Long-term survival following bacteremia or fungemia. JAMA 1995; 274: 807812.
  • 19
    Pedersen G, Schønheyder HC, Sørensen HT. Source of infection and other factors associated with case fatality in community-acquired bacteremia—a Danish population-based cohort study from 1992 to 1997. Clin Microbiol Infect 2003; 9: 793802.
  • 20
    Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448454.
  • 21
    Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006; 53: 441449.
  • 22
    Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379386.